TYMP and neoplasm: While regorafenib is a multi-targeted tyrosine kinase inhibitor that blocks multiple kinases involved in tumor angiogenesis and oncogenesis,[7] trifluridine/tipiracil is an oral combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, in a molar ratio of 1:0.5.